139 related articles for article (PubMed ID: 30763907)
1. Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study.
Zecca C; Pavelek Z; Přikrylová K; Ghielmetti M; Beeler A; Gobbi C
Mult Scler Relat Disord; 2019 May; 30():104-109. PubMed ID: 30763907
[TBL] [Abstract][Full Text] [Related]
2. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
[TBL] [Abstract][Full Text] [Related]
3. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.
Eagle T; Stuart F; Chua AS; LaRussa A; Leclaire K; Cook SL; Chitnis T; Weiner HL; Glanz BI; Healy BC
Mult Scler Relat Disord; 2017 Nov; 18():196-201. PubMed ID: 29141809
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
[TBL] [Abstract][Full Text] [Related]
5. Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a.
Limmroth V; Gerbershagen K
Expert Opin Drug Deliv; 2014 Dec; 11(12):1969-78. PubMed ID: 25255732
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
Saida T; Kira J; Ueno Y; Harada N; Hirakata T
Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon beta-1a for the treatment of relapsing multiple sclerosis: A case series.
Hendin BA
Mult Scler Relat Disord; 2018 Nov; 26():33-36. PubMed ID: 30216756
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.
Beer K; Müller M; Hew-Winzeler AM; Bont A; Maire P; You X; Foulds P; Mårlind J; Curtius D
BMC Neurol; 2011 Nov; 11():144. PubMed ID: 22074056
[TBL] [Abstract][Full Text] [Related]
9. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Calkwood J; Cree B; Crayton H; Kantor D; Steingo B; Barbato L; Hashmonay R; Agashivala N; McCague K; Tenenbaum N; Edwards K
BMC Neurol; 2014 Nov; 14():220. PubMed ID: 25424122
[TBL] [Abstract][Full Text] [Related]
10. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
12. From high- to low-frequency administered interferon-beta for multiple sclerosis: a multicenter study.
Prosperini L; Mancinelli CR; Pozzilli C; Grasso MG; Clemenzi A; Collorone S; Pontecorvo S; Francia A; Villani V; Koudriavtseva T; Buttari F; Centonze D; Di Battista G; Frisullo G; Galgani S; Gasperini C
Eur Neurol; 2014; 71(5-6):233-41. PubMed ID: 24480868
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
Hupperts R; Becker V; Friedrich J; Gobbi C; Salgado AV; Sperling B; You X
Expert Opin Drug Deliv; 2015 Jan; 12(1):15-25. PubMed ID: 25430947
[TBL] [Abstract][Full Text] [Related]
14. A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-β1a in multiple sclerosis patients.
Mallucci G; Patti F; Brescia Morra V; Buccafusca M; Moiola L; Amato MP; Ferraro E; Trojano M; Zaffaroni M; Mirabella M; Moscato G; Plewnia K; Zipoli V; Puma E; Bergamaschi R;
Mult Scler Relat Disord; 2020 May; 40():101952. PubMed ID: 32007656
[TBL] [Abstract][Full Text] [Related]
15. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
16. [Teaching intramuscular self-injection in patients with multiple sclerosis reaching interferon beta-1a: evaluation of a descriptive multicenter program].
Visy JM; Gentin M; Bazerque C;
Presse Med; 2007 Jun; 36(6 Pt 1):841-50. PubMed ID: 17482792
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
Comi G; De Stefano N; Freedman MS; Barkhof F; Uitdehaag BM; de Vos M; Marhardt K; Chen L; Issard D; Kappos L
J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):285-294. PubMed ID: 28039317
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study.
Saiz A; Mora S; Blanco J;
Neurologia; 2015 May; 30(4):214-22. PubMed ID: 24484756
[TBL] [Abstract][Full Text] [Related]
19. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis.
Mokhber N; Azarpazhooh A; Orouji E; Khorram B; Modares Gharavi M; Kakhi S; Khallaghi H; Azarpazhooh MR
Psychiatry Clin Neurosci; 2015 Oct; 69(10):649-57. PubMed ID: 25907350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]